Russia Biosimilars Market Size & Outlook, 2020-2027
Russia biosimilars market, 2016-2027 (US$M)
Related Markets
Russia biosimilars market highlights
- The Russia biosimilars market generated a revenue of USD 145.8 million in 2020 and is expected to reach USD 356.8 million by 2027.
- The Russia market is expected to grow at a CAGR of 13.6% from 2021 to 2027.
- In terms of segment, recombinant non-glycosylated proteins was the largest revenue generating product in 2020.
- Recombinant Glycosylated Proteins is the most lucrative product segment registering the fastest growth during the forecast period.
Biosimilars market data book summary
| Market revenue in 2020 | USD 145.8 million |
| Market revenue in 2027 | USD 356.8 million |
| Growth rate | 13.6% (CAGR from 2020 to 2027) |
| Largest segment | Recombinant non-glycosylated proteins |
| Fastest growing segment | Recombinant Glycosylated Proteins |
| Historical data | 2016 - 2019 |
| Base year | 2020 |
| Forecast period | 2021 - 2027 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins |
| Key market players worldwide | Amgen Inc, Roche, Sandoz Group AG ADR, Dr. Reddy’s Laboratories, Teva Pharmaceutical Industries Ltd, Pfizer Inc, Samsung Bioepis, Biocon, Viatris Inc, Celltrion Healthcare, AbbVie Inc |
Other key industry trends
- In terms of revenue, Russia accounted for 1.1% of the global biosimilars market in 2020.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2027.
- In Europe, Germany biosimilars market is projected to lead the regional market in terms of revenue in 2027.
- UK is the fastest growing regional market in Europe and is projected to reach USD 2,105.2 million by 2027.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Biosimilars Market Scope
Biosimilars Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Russia biosimilars market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biosimilars market will help companies and investors design strategic landscapes.
Recombinant non-glycosylated proteins was the largest segment with a revenue share of 53.22% in 2020. Horizon Databook has segmented the Russia biosimilars market based on recombinant non-glycosylated proteins, recombinant glycosylated proteins covering the revenue growth of each sub-segment from 2016 to 2027.
Growing number of approvals for biosimilars is anticipated to boost the market in Russia during the forecast period. For instance, in January 2016, the Russian Federation’s Ministry of Health approved Herticad, a biosimilar of Roche’s Herceptin, making it the first trastuzumab biosimilar that was approved in the country.
Russia is encouraging the development of biosimilars to help cut the high costs of healthcare, reduce the reliance on imported products, and increase local pharmaceutical production. Thus, rise in drug approvals is expected to be one of the major factors anticipated to boost the adoption of biosimilars in Russia.
The return on investment for biosimilar drugs in the country is not that high as it was in the past, because of the costs that were required to meet national regulations. Therefore, fewer companies are developing biosimilars and most drugs in Russia are imported.
Reasons to subscribe to Russia biosimilars market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Russia biosimilars market databook
-
Our clientele includes a mix of biosimilars market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Russia biosimilars market , including forecasts for subscribers. This country databook contains high-level insights into Russia biosimilars market from 2016 to 2027, including revenue numbers, major trends, and company profiles.
Partial client list
Russia biosimilars market size, by product, 2016-2027 (US$M)
Russia Biosimilars Market Outlook Share, 2020 & 2027 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
